Efficacy and safety evaluation of adalimumab for psoriatic arthritis: A meta-analysis.

What was studied

This review pooled randomized trials of adalimumab in psoriatic arthritis. The team searched many English and Chinese databases up to June 10, 2026. In all, 17 studies were included. They covered 5655 patients. They were compared with control groups. The team looked at effects and at side effects.

What they found

Adalimumab significantly improved joint response measures ACR20, ACR50 and ACR70. It also improved skin measures PASI75, PASI90 and PASI100. Other measures improved too, such as enthesitis resolution and minimal disease activity. Overall and serious adverse events did not rise significantly. Stopping because of side effects did not rise either. Liver enzymes ALT and AST rose significantly.

What it means for patients

The authors say adalimumab showed benefit in psoriatic arthritis. They see the liver enzyme rise as a potential signal of liver harm. They say liver checks may be warranted during treatment.

Why it is not certain yet

The abstract does not say how well the studies were done. The abstract does not give how long people were followed. Liver harm is called a potential signal, not a proven effect. A review can only be as good as the studies in it.

Source

Efficacy and safety evaluation of adalimumab for psoriatic arthritis: A meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.